Investor Criteria for FemTech Seed and Series A Rounds

FemTech is growing fast and getting harder to raise money for at the same time. That's the whole contradiction this piece sits inside, and the numbers make the tension obvious. Astute Analytica pegged the global market at $56.50 billion in 2024, headed to $206.84 billion by 2033. Meanwhile Galen Growth's August 2025 numbers show FemTech's slice of digital health capital actually fell, down to 8.5% in 2024 from 14.7% in 2020. Bigger market, smaller piece of the funding pie. Which means the bar for getting funded went up, and this piece walks through exactly how much.

Some of this goes back further than the current slowdown. Grand View Research has women's health sitting around 2% of total health tech funding, historically, and you can read that number two ways. Either it's proof the sector is wildly undervalued, or it's a quiet admission that the plumbing (billing codes, payer contracts, clinical protocols) isn't built yet. Silicon Valley Bank clocked $2.6 billion in women's health VC for 2024, which sounds like a lot until you see who's actually getting it, and what they had to show up with to get it.

How FemTech capital is actually distributed across stages and deal sizes

New Market Pitch's July 2026 numbers show seed and Series A made up 78.26% of all disclosed FemTech deals over the twelve months ending June 2026. Most of the activity, by count, but count and capital are different animals: seed rounds were 52.17% of deals and only 9.28% of disclosed dollars, about $38.3 million spread across 12 deals.

Run the math and the median seed round is $6 million. The average is $17.9 million. That gap isn't a rounding error, it's a handful of huge raises pulling the average way above where most founders actually land. Take out anything over $50 million and deal sizes have barely moved from 2022 to 2025. The typical raise hasn't grown; the tail just got longer.

And that tail is doing a lot of work. In 2024, deals over $50 million were 16% of deal count but 66% of total capital. A small number of companies are eating most of the meal, and everyone else is splitting what's left on the table.

Here's what nobody likes hearing: most companies that raise a seed round, even a solid Series A, don't make it to Series B. Investors know this going in. It shapes how they look at you from day one, because the real question at Series A isn't just "is this good," it's "does this survive the gap before the next round." Everything covered below, the clinical bar, the regulatory checklist, who's on the team, exists because investors are trying to guess who clears that gap.

How investors define clinical credibility at the seed stage — and what they do not accept as a substitute

Christian Leybold, Managing Partner at Headline, said something in an April 2026 DLA Piper piece that stuck with me: regulatory-grade clinical validation changed the entire conversation. Once software-driven women's health products started clearing as actual regulated medical devices, FemTech stopped living under "wellness" and started getting graded as healthcare infrastructure. That's not a subtle shift, and it changes what you need walking into a seed pitch.

Nobody's expecting FDA clearance at seed, that would be like expecting a toddler to enter a marathon. But investors want a few things nailed down anyway. A female-specific biological mechanism that's actually named, not "women" bolted on as a demographic. A clinical advisory board with real domain depth, which BetterWomanHealth's December 2025 research treats less as a credibility badge and more as risk mitigation. A stated regulatory classification, even a rough one, with some logic for how you get from here to clearance. And some early pilot or feasibility data, not a mountain of it, just something. Show up with zero data at seed and that reads as a flag, not a stage-appropriate gap.

What gets rejected outright: women-specific branding slapped on an otherwise generic product. Pink packaging on a supplement reads as marketing arbitrage, not a clinical thesis, and New Market Pitch's July 2026 research quotes investors calling it exactly that. The bar keeps rising too, since larger rounds increasingly cite FDA clearance, real trials, hospital partnerships, physician-led care, or diagnostic capability. Seed founders should be building toward that even before anyone expects them to hit it.

DLA Piper's April 2026 framing sums it up: investors want a strong product, solid data, real revenue visibility, and a believable path to scale. All four have to show up together, or the pitch doesn't land.

What Series A investors require in terms of clinical evidence and regulatory progress

Seed is where you say "here's the plan." Series A is where the plan needs receipts, since data now outweighs decks and the regulatory question that got a hand-wave at seed needs an actual answer.

Sidley Austin LLP's February 2023 guidance spells out what diligence checks: which regulatory framework applies, whether you need FDA clearance or CE marking or both, and what your market-access timeline does to your burn rate getting there. A founder who can't classify their own product, or can't explain the timeline with any precision, fails diligence. Full stop.

Reimbursement is its own gate, weighed just as heavily. Vantage BioMed's April 2026 research makes the point sharp: an FDA-cleared device that beats everything else clinically can still be a broken business if the reimbursement rate doesn't cover what it costs to make and deliver. Vantage flags a specific failure mode here, founders assuming commercial launch within 12 months of clearance, with a reimbursement strategy that amounts to "Medicare will probably see the value eventually." Investors hear that as a hope, not a plan, and they can tell the difference.

Worth asking why fertility and reproductive health pull outsized capital relative to everything else. Part of the answer is boring: those categories already have established regulatory pathways and, in some cases, employer or insurer reimbursement already built, per DLA Piper's April 2026 analysis. At Series A, hospital partnerships, pilot contracts, payer conversations already underway all read as de-risking signals. Founders without any of that are in a much harder room.

Put regulatory and reimbursement side by side and you get the real Series A test: clinical validation that can't turn into an actual payment mechanism isn't investable yet, no matter how good the underlying science is.

Which subsectors investors are actively backing and why the list has shifted since 2022

Fertility and IVF technology led from 2022 through 2025, pulling in roughly $811 million across 49 deals, about 34% of total FemTech capital, per New Market Pitch's July 2026 data. Makes sense: IVF clinics have predictable revenue, employer-sponsored fertility benefits expanded hard post-pandemic, and AI plus biotech gains have made measurable outcome improvements believable. But the category is crowded now at seed, and "AI for IVF" alone doesn't work as a pitch anymore. You need a specific clinical wedge, sharper than the category label.

Menopause has overtaken fertility as Dealroom's top-ranked hot subsector, funding up 9% over three years to $104 million in 2025. Why now? Astute Analytica and Globe Newswire reported in January 2026 that 75% of women seeking midlife care had been ignored by the traditional healthcare system before that. That's a huge population sitting there, underserved, for decades, and companies like Midi Health and Alloy are scaling into that gap fast.

AI-powered diagnostics had a real breakout in 2025 too. Ataraxis AI raised $20.4 million for breast cancer diagnostics, Visby Medical raised $55 million for STI testing, and Emm raised $9 million for menstrual biosensing, per New Market Pitch. Three completely different applications, one shared signal: investors have appetite across the diagnostic spectrum, not just one narrow niche.

Then there's at-home metagenomic and microbiome testing, interesting because the defensibility comes from stacking, not any single feature. Proprietary biomarker data, patented assay methods, clinical validation, subscription lock-in, all compounding together. Healthcare Digital's May 2026 coverage points to Evvy (vaginal microbiome sequencing) and Daye (diagnostic tampons with microbiome analysis) as examples that can flag conditions like endometriosis or PCOS before a patient even shows symptoms.

Pregnancy care and menstrual health tools, meanwhile, show plenty of deal activity but a thin slice of total capital, per New Market Pitch. Innovation is happening there, but scale money hasn't shown up yet. The takeaway for founders: your subsector shapes how the pitch gets read before anyone opens the deck. Menopause, AI diagnostics, and microbiome testing carry structural tailwind right now. Everywhere else, you're building the tailwind yourself.

Why business model design is now an investor criterion, not an operational decision

Business model used to be the thing founders figured out after the check cleared. Now it's scrutinized on the front end. FemTech has been pivoting hard from direct-to-consumer toward B2B and clinical channels, and investors watched D2C unit economics get worse across the sector before deciding, pretty openly, that they'd rather back stable, recurring B2B revenue.

Maven Clinic is the case everyone points to. Its $1.7 billion valuation in late 2024 rested partly on a demonstrated 2:1 clinical ROI for employers, mostly from cutting expensive outcomes like unnecessary C-sections, per Astute Analytica and Globe Newswire's January 2026 reporting. That's a number an employer's CFO can put in a spreadsheet and defend.

The employer benefits channel is a genuinely proven distribution path at this point, not a hypothesis. Emergen Research found 40% of US employers offered fertility coverage in 2024, and Mordor Intelligence's 2026 research shows 75% plan to expand women's health benefits further. Progyny posted $298.4 million in Q4 2024 revenue across 473 clients, which gives you a sense of the scale possible once you're plugged into employer budgets. Carrot Fertility and Maven Clinic have both shown employers will pay for this at the platform level, not as a one-off perk.

Tracy Warren of Astarte Ventures put it about as bluntly as you can, as quoted by HTD Health: "You've got to pitch a highly profitable business with rapid growth and a sustaining, recurring revenue model. Those are the things that get any investor's attention." The Mean CEO Blog's August 2026 piece adds a useful wrinkle: the model has to match the care path. DTC, B2B employer, insurer, clinic, or some service-plus-software hybrid, each one only works when the buyer and the outcome actually line up. Mismatch those two and no amount of clinical polish saves the pitch.

At seed, investors want the model hypothesis and a reason to believe someone will pay eventually. At Series A, they want proof someone already is: signed LOIs, active pilots, contracts with a name on them. A D2C-only pitch with no plan to touch employer or clinical channels gets pushback at Series A, consistently, because the market has already shown what scales and what doesn't.

Team composition signals investors use to assess execution risk in FemTech specifically

FemTech team diligence carries weight beyond the usual startup checklist. Nixon Peabody LLP's May 2026 research lays out a healthcare-specific list investors actually use. Founders or key hires need real experience spanning both healthcare and technology, not just one side of that fence. Low turnover among clinical, regulatory, and engineering leaders reads as organizational health; its absence reads as instability, plain and simple. A dedicated compliance officer, chief medical officer, and chief information security officer on staff signal the company can actually handle regulated health data and regulated health claims.

Clinical advisory board quality comes up again here, worth repeating why. BetterWomanHealth's December 2025 research points to companies that stumbled specifically because founders didn't understand the clinical nuance of the problem they were solving. A strong CAB tells investors the company has access to expertise it hasn't built in-house yet. At seed, that CAB carries more weight, since internal clinical depth is usually thin. By Series A, investors expect that expertise moving in-house, not still parked with advisors who dial in for quarterly calls.

Regulatory experience is its own asset, separate from the clinical piece entirely. A regulatory affairs lead, or even just an advisor, who's actually filed an FDA submission before means the company isn't learning regulatory strategy for the first time on investor money. That's a different risk profile than a team guessing its way through it in real time.

Female founders and clinical domain expertise show up together often in this sector, and investors notice the pattern. But they don't treat gender or lived experience as a substitute for operational depth, and they shouldn't. The red flag that keeps showing up, and keeps getting passed on, is a technically sharp team with zero clinical or regulatory experience and no visible plan to close that gap. That combination has failed often enough that it's become its own pattern recognition problem.

How to define the market in a FemTech pitch so the sizing argument is credible to investors

The single most common mistake in FemTech pitches: citing a huge total addressable market for "women" or "women's health" with no clinical segmentation underneath it. That reads as demographic targeting in a bigger font, not real market sizing, and investors spot it fast.

There's a real distinction here worth sitting with. A market built around a specific female biological condition, with a named clinical population you can actually count, is investable. A market defined by gender alone, as a targeting parameter bolted onto an otherwise generic product, carries a lot less weight, at least not at any real scale.

The underfunding gap cuts both ways here. Grand View Research's figure, roughly 2% of health tech funding historically going to women's health, is something founders love citing as proof of opportunity. Fair enough, but investors hear the same number and think about the infrastructure that isn't built yet, the missing billing codes, the payer relationships that don't exist. Same data point, read two different ways depending on which side of the table you sit on. The $100 million in federal women's health R&D funding allocated in March 2024 is a real policy tailwind, sure, but it doesn't turn into reimbursement tomorrow.

Bottom-up, subsector-specific sizing beats top-down guesswork every time. In fertility, the employer benefits channel is documented and growing: that 40% adoption rate among large US employers in 2024, from Mordor Intelligence, gives you a real beachhead to size against. In menopause, that 75% figure of previously underserved women from Astute Analytica and Globe Newswire is a concrete clinical population, not a demographic guess pulled off a census table.

Market definition, in the end, doubles as a proxy for founder clarity. A founder who can't name the clinical addressable market with precision usually doesn't have a coherent go-to-market plan either, and investors have seen that correlation hold often enough to trust it. What works is bottoms-up sizing built from clinical incidence rates and named patient populations, standing on its own two feet rather than leaning on a top-line market report with "women" in the header and nothing underneath it.